Cas:63624-27-1 3,4-Dimethoxybenzenesulfonamide manufacturer & supplier

We serve Chemical Name:3,4-Dimethoxybenzenesulfonamide CAS:63624-27-1 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

3,4-Dimethoxybenzenesulfonamide

Chemical Name:3,4-Dimethoxybenzenesulfonamide
CAS.NO:63624-27-1
Synonyms:3,4-Dimethoxy-benzolsulfonamid;3,4-dimethoxybenzenesulphonamide;3,4-dimethoxy-benzenesulfonic acid amide;3,4-dimethoxybenzene-1-sulfonamide;3,4-Dimethoxy-benzolsulfonsaeure-amid;3.4-Dimethoxybenzolsulfamid
Molecular Formula:C8H11NO4S
Molecular Weight:217.24200
HS Code:2935009090

Physical and Chemical Properties:
Melting point:N/A
Boiling point:379ºC at 760 mmHg
Density:1.305g/cm3
Index of Refraction:1.536
PSA:87.00000
Exact Mass:217.04100
LogP:2.13230

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like 3,4-Dimethoxy-benzolsulfonamid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,3.4-Dimethoxybenzolsulfamid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3.4-Dimethoxybenzolsulfamid Use and application,3,4-Dimethoxy-benzolsulfonamid technical grade,usp/ep/jp grade.


Related News: A thorough safety and risk analysis procedure should be administered at an appropriate time with documentation that adheres to the rules and regulations set forth by the regulatory authorities. 2-Cyclohexen-1-one, 3-(3-furanylmethyl)-4-(1-methylethyl)- manufacturers Patients having Zynteglo treatment for beta thalassaemia also need conditioning treatment to clear out their bone marrow cells before receiving Zynteglo. Healthcare professionals should therefore explicitly inform patients receiving Zynteglo of the increased risk of blood cancers from medicines used in conditioning treatments. 3-Methoxy-Δ1,3,5(10),8-14β-oestratetraen-17α-ol suppliers Orchard’s decision last year to put OTL-101 on the back burner left patients with no way to access a seemingly effective therapy for a condition that can kill children before they reach the age of one. (E)-4-(tert-butyl)-2,2,8,8-tetramethyl-6-methylene-3,7-dioxa-2,8-disilanon-4-ene vendor & factory.